Home
Therapeutic Categories
- BACK
- Therapeutic Categories
- Allergy & Immunology
  - BACK
  - Allergy & Immunology
  - Chronic Spontaneous Urticaria
  - Food Allergies
  - Pediatric Food Allergies
  - Search for:
- Dermatology
  - BACK
  - Dermatology
  - Atopic Dermatitis
  - Plaque Psoriasis
  - Search for:
- Endocrinology
  - BACK
  - Endocrinology
  - Type 2 Diabetes
  - Search for:
- Gastroenterology
  - BACK
  - Gastroenterology
  - Crohn's Disease
  - Ulcerative Colitis
  - Search for:
- Hematology
  - BACK
  - Hematology
  - Chronic Immune Thrombocytopenia
  - Paroxysmal Nocturnal Hemoglobinuria
  - Sickle Cell Disease
  - Search for:
- Hepatology
  - BACK
  - Hepatology
  - Liver Fibrosis
  - Search for:
- Infectious Diseases
  - BACK
  - Infectious Diseases
  - Adolescent Vaccinations
  - COVID-19 Prevention
  - Influenza
  - Search for:
- Nephrology
  - BACK
  - Nephrology
  - IgAN
  - IgAN & C3G
  - Renal Transplant Maintenance
  - Search for:
- Neurology
- Oncology
- Ophthalmology
  - BACK
  - Ophthalmology
  - Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema
  - Wet AMD
  - Search for:
- Osteoporosis
  - BACK
  - Osteoporosis
  - Osteoporosis
  - Search for:
- Psychiatry
  - BACK
  - Psychiatry
  - Major Depressive Disorder
  - Schizophrenia
  - Tardive Dyskinesia
  - Search for:
- Pulmonology
  - BACK
  - Pulmonology
  - Asthma
  - COPD
  - Interstitial Lung Disease
  - Search for:
- Rheumatology
  - BACK
  - Rheumatology
  - Psoriatic Arthritis
  - Rheumatoid Arthritis
  - Systemic Lupus Erythematosus
  - Search for:
- Urology
  - BACK
  - Urology
  - Uncomplicated Urinary Tract Infections
  - Search for:
- Search for:
Conference Reporter
Expert Directory
About Expert Perspectives
Login/Register
Search for:

experspadmin

Emerging Immuno-Myeloid Therapies in MDS and AML

Emerging Immuno-Myeloid Therapies in MDS and AML

expert roundtables
By Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; Rami S. Komrokji, MD

Improving Response Durability in High-Risk MDS and AML

Improving Response Durability in High-Risk MDS and AML

expert roundtables
By Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; Rami S. Komrokji, MD

Integrating Genomics Into the Classification and Management of MDS

Integrating Genomics Into the Classification and Management of MDS

expert roundtables
By Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; Rami S. Komrokji, MD

Promising Lower-Intensity Regimens for Patients With High-Risk MDS and AML

Promising Lower-Intensity Regimens for Patients With High-Risk MDS and AML

expert roundtables
By Andrew M. Brunner, MD; Courtney D. DiNardo, MD, MSCE; Rami S. Komrokji, MD

$Refractory or Difficult-to-Treat Tardive Dyskinesia$

Refractory or Difficult-to-Treat Tardive Dyskinesia

patient care perspectives
By Rakesh Jain, MD, MPH

Load More

2026 Expert Perspectives®

Privacy Policy Terms of Service About Expert Perspectives

Your California Privacy Rights Do Not Sell My Personal Information

Login Expert Perspectives

Forgot Password?

or Create an Account

Create an Account

Forgot Password?